{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:37:15Z","timestamp":1777480635252,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70115116"],"award-info":[{"award-number":["70115116"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2024.050.1"],"award-info":[{"award-number":["2024.050.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2024.050.1"],"award-info":[{"award-number":["2024.050.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","award":["RG79"],"award-info":[{"award-number":["RG79"]}],"id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of clonal B cells. Although targeted therapies have improved outcomes, resistance remains a challenge, particularly in high-risk patients with TP53 mutations or unmutated immunoglobulin heavy-chain variable region (IGHV) genes (U-CLL). Ferroptosis, a regulated, iron-dependent form of cell death, may represent an exploitable vulnerability in CLL; however, its mechanisms and clinical relevance remain poorly understood. Here, we identified IGHV status and microenvironmental cues as determinants of ferroptosis sensitivity. Using CLL cell lines, patient samples, and in vivo models, we show that CLL cells exhibit elevated basal levels of lipid peroxides and labile iron, predisposing them to ferroptosis. However, stromal interactions enhance cystine import and glutathione synthesis, thereby mitigating susceptibility to ferroptosis. Mechanistically, BTK inhibition sensitizes CLL cells to ferroptosis by increasing the transferrin receptor (TFRC, CD71) and increasing the intracellular Fe\u00b2\u207a level. High TFRC expression was associated with improved survival in two independent CLL patient cohorts, supporting its therapeutic and prognostic relevance. Combining ibrutinib with the GPX4 inhibitor RSL3 enhances ferroptosis and improves antileukemic efficacy in vivo. CLL cells with mutated IGHV genes (M-CLL) display greater TFRC expression and ferroptosis sensitivity than U-CLL cells do. This resistance can be overcome by ibrutinib-mediated TFRC induction or via metabolic targeting of fatty acid metabolism. Notably, ACSL1 is selectively upregulated in U-CLL cells and represents a targetable metabolic enhancer of ferroptosis sensitivity, as shown in vivo. Our findings reveal that TFRC and ACSL1 are functionally distinct yet targetable nodes that govern ferroptosis vulnerability in CLL patients and may guide novel therapeutic strategies for high-risk patients.<\/jats:p>","DOI":"10.1038\/s41392-025-02535-x","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:02:25Z","timestamp":1767571345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunoglobulin heavy-chain status and stromal interactions shape ferroptosis sensitivity in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2911-8830","authenticated-orcid":false,"given":"Martin","family":"B\u00f6ttcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Reemts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Hengeveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5067-7843","authenticated-orcid":false,"given":"Romy","family":"B\u00f6ttcher-Loschinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Bhuria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Materna-Reichelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Durdam","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasa","family":"Stojanovi\u0107 Gu\u017evi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-2218","authenticated-orcid":false,"given":"Wolfgang","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7890-9845","authenticated-orcid":false,"given":"Thorsten","family":"Zenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denny","family":"Schanze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Zenker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton W.","family":"Langerak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-6660","authenticated-orcid":false,"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2535_CR1","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek, M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131, 2745\u20132760 (2018).","journal-title":"Blood"},{"key":"2535_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/ng.2652","volume":"45","author":"SI Berndt","year":"2013","unstructured":"Berndt, S. I. et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet 45, 868\u2013876 (2013).","journal-title":"Nat Genet"},{"key":"2535_CR3","unstructured":"Diez, P. et al. Tonic signaling of the B-cell antigen-specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages. Mol Oncol, (2025)."},{"key":"2535_CR4","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","volume":"91","author":"S Kitada","year":"1998","unstructured":"Kitada, S. et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 91, 3379\u20133389 (1998).","journal-title":"Blood"},{"key":"2535_CR5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood-2018-01-826008","volume":"132","author":"P Dreger","year":"2018","unstructured":"Dreger, P. et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood 132, 892\u2013902 (2018).","journal-title":"Blood"},{"key":"2535_CR6","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1182\/blood-2013-10-532200","volume":"123","author":"R Jitschin","year":"2014","unstructured":"Jitschin, R. et al. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood 123, 2663\u20132672 (2014).","journal-title":"Blood"},{"key":"2535_CR7","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1182\/blood-2014-10-607036","volume":"125","author":"R Jitschin","year":"2015","unstructured":"Jitschin, R. et al. Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling. Blood 125, 3432\u20133436 (2015).","journal-title":"Blood"},{"key":"2535_CR8","doi-asserted-by":"crossref","unstructured":"Bottcher, M. et al. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis. J Immunother Cancer. 9, (2021).","DOI":"10.1136\/jitc-2020-001889"},{"key":"2535_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon, S. J. & Olzmann, J. A. The cell biology of ferroptosis. Nat Rev Mol Cell Biol 25, 424\u2013442 (2024).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2535_CR10","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/cdd.2011.30","volume":"18","author":"M Olsson","year":"2011","unstructured":"Olsson, M. & Zhivotovsky, B. Caspases and cancer. Cell Death Differ 18, 1441\u20131449 (2011).","journal-title":"Cell Death Differ"},{"key":"2535_CR11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1182\/blood.2020009404","volume":"138","author":"A Schmitt","year":"2021","unstructured":"Schmitt, A. et al. Dimethyl fumarate induces ferroptosis and impairs NF-kappaB\/STAT3 signaling in DLBCL. Blood 138, 871\u2013884 (2021).","journal-title":"Blood"},{"key":"2535_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/blood.2022019274","volume":"142","author":"A Schmitt","year":"2023","unstructured":"Schmitt, A. et al. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood 142, 1143\u20131155 (2023).","journal-title":"Blood"},{"key":"2535_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ebiom.2016.12.001","volume":"15","author":"DR Friedman","year":"2017","unstructured":"Friedman, D. R. Lipids and Their Effects in Chronic Lymphocytic Leukemia. EBioMedicine 15, 2\u20133 (2017).","journal-title":"EBioMedicine"},{"key":"2535_CR14","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","volume":"114","author":"AV Kurtova","year":"2009","unstructured":"Kurtova, A. V. et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114, 4441\u20134450 (2009).","journal-title":"Blood"},{"key":"2535_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/ncb2432","volume":"14","author":"W Zhang","year":"2012","unstructured":"Zhang, W. et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukemia. Nat Cell Biol 14, 276\u2013286 (2012).","journal-title":"Nat Cell Biol"},{"key":"2535_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175526","volume":"943","author":"SA Setiawan","year":"2023","unstructured":"Setiawan, S. A. et al. Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma. Eur J Pharmacol 943, 175526 (2023).","journal-title":"Eur J Pharmacol"},{"key":"2535_CR17","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","volume":"123","author":"SE Herman","year":"2014","unstructured":"Herman, S. E. et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 123, 3286\u20133295 (2014).","journal-title":"Blood"},{"key":"2535_CR18","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1080\/10428194.2018.1439167","volume":"59","author":"U Rozovski","year":"2018","unstructured":"Rozovski, U. et al. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma 59, 2686\u20132691 (2018).","journal-title":"Leuk Lymphoma"},{"key":"2535_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia, B., Vandenabeele, P. & Vanden Berghe, T. Targeting Ferroptosis to Iron Out Cancer. Cancer Cell 35, 830\u2013849 (2019).","journal-title":"Cancer Cell"},{"key":"2535_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/j.seminhematol.2024.05.002","volume":"61","author":"A Floerchinger","year":"2024","unstructured":"Floerchinger, A. & Seiffert, M. Lessons learned from the Emicro-TCL1 mouse model of CLL. Semin Hematol 61, 194\u2013200 (2024).","journal-title":"Semin Hematol"},{"key":"2535_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1600-0609.2009.01369.x","volume":"84","author":"MR Mansouri","year":"2010","unstructured":"Mansouri, M. R. et al. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia. Eur J Hematol 84, 109\u2013116 (2010).","journal-title":"Eur J Hematol"},{"key":"2535_CR22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.chembiol.2020.03.011","volume":"27","author":"A Anandhan","year":"2020","unstructured":"Anandhan, A. et al. Breakdown of an Ironclad Defense System: The Critical Role of NRF2 in Mediating Ferroptosis. Cell Chem Biol 27, 436\u2013447 (2020).","journal-title":"Cell Chem Biol"},{"key":"2535_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood-2016-01-683128","volume":"128","author":"M Pasikowska","year":"2016","unstructured":"Pasikowska, M. et al. Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. Blood 128, 563\u2013573 (2016).","journal-title":"Blood"},{"key":"2535_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70064","volume":"8","author":"D Friedman","year":"2024","unstructured":"Friedman, D. et al. Proliferating CLL cells express high levels of CXCR4 and CD5. Hemasphere 8, e70064 (2024).","journal-title":"Hemasphere"},{"key":"2535_CR25","doi-asserted-by":"publisher","first-page":"10559","DOI":"10.1073\/pnas.95.18.10559","volume":"95","author":"K Pantopoulos","year":"1998","unstructured":"Pantopoulos, K. & Hentze, M. W. Activation of iron regulatory protein-1 by oxidative stress in vitro. Proc Natl Acad Sci USA 95, 10559\u201310563 (1998).","journal-title":"Proc Natl Acad Sci USA"},{"key":"2535_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41420-023-01383-4","volume":"9","author":"F Maccarinelli","year":"2023","unstructured":"Maccarinelli, F. et al. Iron supplementation enhances RSL3-induced ferroptosis to treat naive and prevent castration-resistant prostate cancer. Cell Death Discov 9, 81 (2023).","journal-title":"Cell Death Discov"},{"key":"2535_CR27","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41418-022-00943-y","volume":"29","author":"Y Liu","year":"2022","unstructured":"Liu, Y. & Gu, W. p53 in ferroptosis regulation: the new weapon for the old guardian. Cell Death Differ 29, 895\u2013910 (2022).","journal-title":"Cell Death Differ"},{"key":"2535_CR28","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.3324\/haematol.2018.203067","volume":"104","author":"J Lu","year":"2019","unstructured":"Lu, J. et al. Energy metabolism is codetermined by genetic variants in chronic lymphocytic leukemia and influences drug sensitivity. Hematologica 104, 1830\u20131840 (2019).","journal-title":"Hematologica"},{"key":"2535_CR29","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3109\/09553000903258889","volume":"85","author":"UG Sattler","year":"2009","unstructured":"Sattler, U. G. & Mueller-Klieser, W. The antioxidant capacity of tumor glycolysis. Int J Radiat Biol 85, 963\u2013971 (2009).","journal-title":"Int J Radiat Biol"},{"key":"2535_CR30","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1182\/blood.2020009741","volume":"138","author":"F Meier-Abt","year":"2021","unstructured":"Meier-Abt, F. et al. The protein landscape of chronic lymphocytic leukemia. Blood 138, 2514\u20132525 (2021).","journal-title":"Blood"},{"key":"2535_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33385-8","volume":"13","author":"SA Herbst","year":"2022","unstructured":"Herbst, S. A. et al. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. Nat Commun 13, 6226 (2022).","journal-title":"Nat Commun"},{"key":"2535_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41418-019-0352-3","volume":"27","author":"GQ Chen","year":"2020","unstructured":"Chen, G. Q. et al. Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. Cell Death Differ 27, 242\u2013254 (2020).","journal-title":"Cell Death Differ"},{"key":"2535_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22471-y","volume":"12","author":"A Beatty","year":"2021","unstructured":"Beatty, A. et al. Ferroptotic cell death triggered by conjugated linolenic acids is mediated by ACSL1. Nat Commun 12, 2244 (2021).","journal-title":"Nat Commun"},{"key":"2535_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13, 91\u201398 (2017).","journal-title":"Nat Chem Biol"},{"key":"2535_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula, P., Zhuang, L. & Gan, B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12, 599\u2013620 (2021).","journal-title":"Protein Cell"},{"key":"2535_CR36","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.V80.8.2038.2038","volume":"80","author":"R Silber","year":"1992","unstructured":"Silber, R. et al. Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood 80, 2038\u20132043 (1992).","journal-title":"Blood"},{"key":"2535_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"V Del Gaizo Moore","year":"2007","unstructured":"Del Gaizo Moore, V. et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117, 112\u2013121 (2007).","journal-title":"J Clin Invest"},{"key":"2535_CR38","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1182\/blood-2008-04-149815","volume":"112","author":"D Trachootham","year":"2008","unstructured":"Trachootham, D. et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 112, 1912\u20131922 (2008).","journal-title":"Blood"},{"key":"2535_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.exphem.2021.12.193","volume":"106","author":"LA Thurgood","year":"2022","unstructured":"Thurgood, L. A. et al. Lipid uptake in chronic lymphocytic leukemia. Exp Hematol 106, 58\u201367 (2022).","journal-title":"Exp Hematol"},{"key":"2535_CR40","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1357-2725(99)00065-5","volume":"31","author":"NC Andrews","year":"1999","unstructured":"Andrews, N. C. The iron transporter DMT1. Int J Biochem Cell Biol 31, 991\u2013994 (1999).","journal-title":"Int J Biochem Cell Biol"},{"key":"2535_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ng.3465","volume":"48","author":"HH Jabara","year":"2016","unstructured":"Jabara, H. H. et al. A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency. Nat Genet 48, 74\u201378 (2016).","journal-title":"Nat Genet"},{"key":"2535_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11002-5","volume":"10","author":"Y Jiang","year":"2019","unstructured":"Jiang, Y. et al. Iron-dependent histone 3 lysine 9 demethylation controls B-cell proliferation and humoral immune responses. Nat Commun 10, 2935 (2019).","journal-title":"Nat Commun"},{"key":"2535_CR43","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.2119\/molmed.2011.00360","volume":"17","author":"C Calissano","year":"2011","unstructured":"Calissano, C. et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born\/divided and older\/quiescent cells. Mol Med 17, 1374\u20131382 (2011).","journal-title":"Mol Med"},{"key":"2535_CR44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.seminhematol.2023.12.004","volume":"61","author":"AF Vom Stein","year":"2024","unstructured":"Vom Stein, A. F., Hallek, M. & Nguyen, P. H. Role of the tumor microenvironment in CLL pathogenesis. Semin Hematol 61, 142\u2013154 (2024).","journal-title":"Semin Hematol"},{"key":"2535_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41420-024-01800-2","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu, X. et al. Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway. Cell Death Discov 10, 35 (2024).","journal-title":"Cell Death Discov"},{"key":"2535_CR46","doi-asserted-by":"publisher","first-page":"e722","DOI":"10.1097\/HS9.0000000000000722","volume":"6","author":"K Kluckova","year":"2022","unstructured":"Kluckova, K. et al. B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities. Hemasphere 6, e722 (2022).","journal-title":"Hemasphere"},{"key":"2535_CR47","doi-asserted-by":"crossref","unstructured":"Camp, N., Garrett, M., Gopal, A. K. & James, R. Ibrutinib Selects for Cells with Elevated Reactive Oxygen Species and Downregulated Phosphatases. Blood. 134, (2019).","DOI":"10.1182\/blood-2019-124454"},{"key":"2535_CR48","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1016\/j.celrep.2020.02.049","volume":"30","author":"H Feng","year":"2020","unstructured":"Feng, H. et al. Transferrin Receptor Is a Specific Ferroptosis Marker. Cell Rep 30, 3411\u20133423.e3417 (2020).","journal-title":"Cell Rep"},{"key":"2535_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrm3909","volume":"16","author":"TA Rouault","year":"2015","unstructured":"Rouault, T. A. Mammalian iron-sulphur proteins: novel insights into biogenesis and function. Nat Rev Mol Cell Biol 16, 45\u201355 (2015).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2535_CR50","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2010-03-275859","volume":"116","author":"YC Wu","year":"2010","unstructured":"Wu, Y. C. et al. High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood 116, 1070\u20131078 (2010).","journal-title":"Blood"},{"key":"2535_CR51","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/bloodadvances.2022008033","volume":"7","author":"G Couillez","year":"2023","unstructured":"Couillez, G. et al. Flow cytometry as a fast, cost-effective tool to assess IGHV mutational status in CLL. Blood Adv 7, 4701\u20134704 (2023).","journal-title":"Blood Adv"},{"key":"2535_CR52","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5646275","volume":"2022","author":"H Gong","year":"2022","unstructured":"Gong, H. et al. A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia. Biomed Res Int. 2022, 5646275 (2022).","journal-title":"Biomed Res Int."},{"key":"2535_CR53","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1080\/10428194.2021.2020779","volume":"63","author":"JA Burger","year":"2022","unstructured":"Burger, J. A. et al. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma 63, 1375\u20131386 (2022).","journal-title":"Leuk Lymphoma"},{"key":"2535_CR54","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr, P. M. et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv 6, 3440\u20133450 (2022).","journal-title":"Blood Adv"},{"key":"2535_CR55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-018-0561-0","volume":"11","author":"TK Vatsveen","year":"2018","unstructured":"Vatsveen, T. K. et al. Artesunate shows potent anti-tumor activity in B-cell lymphoma. J Hematol Oncol 11, 23 (2018).","journal-title":"J Hematol Oncol"},{"key":"2535_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou, Q. et al. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther 9, 55 (2024).","journal-title":"Signal Transduct Target Ther"},{"key":"2535_CR57","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi, T. et al. Lisocabtagene maraleucel in chronic lymphocytic leukemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicenter, open-label, single-arm, phase 1-2 study. Lancet 402, 641\u2013654 (2023).","journal-title":"Lancet"},{"key":"2535_CR58","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. CD8(+) T cells regulate tumor ferroptosis during cancer immunotherapy. Nature 569, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"2535_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao, P. et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 40, 365\u2013378.e366 (2022).","journal-title":"Cancer Cell"},{"key":"2535_CR60","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","volume":"6","author":"S Gill","year":"2022","unstructured":"Gill, S. et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv 6, 5774\u20135785 (2022).","journal-title":"Blood Adv"},{"key":"2535_CR61","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jcyt.2013.02.010","volume":"15","author":"M Krampera","year":"2013","unstructured":"Krampera, M. et al. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15, 1054\u20131061 (2013).","journal-title":"Cytotherapy"},{"key":"2535_CR62","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1182\/blood-2008-09-181040","volume":"113","author":"D Mougiakakos","year":"2009","unstructured":"Mougiakakos, D., Johansson, C. C. & Kiessling, R. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood 113, 3542\u20133545 (2009).","journal-title":"Blood"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02535-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02535-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02535-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:02:27Z","timestamp":1767571347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02535-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2535"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02535-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}